Rigel Pharmaceuticals Inc (RIGL) - Total Assets
Based on the latest financial reports, Rigel Pharmaceuticals Inc (RIGL) holds total assets worth $504.61 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does Rigel Pharmaceuticals Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Rigel Pharmaceuticals Inc - Total Assets Trend (1999–2025)
This chart illustrates how Rigel Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Rigel Pharmaceuticals Inc to evaluate the quality of earnings relative to operating cash generation.
Rigel Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Rigel Pharmaceuticals Inc's total assets of $504.61 Million consist of 46.8% current assets and 53.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 7.9% |
| Accounts Receivable | $51.76 Million | 10.1% |
| Inventory | $11.51 Million | 2.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $24.75 Million | 4.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Rigel Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Rigel Pharmaceuticals Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rigel Pharmaceuticals Inc's current assets represent 46.8% of total assets in 2025, a decrease from 49.7% in 1999.
- Cash Position: Cash and equivalents constituted 7.9% of total assets in 2025, down from 34.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 10.1% of total assets.
Rigel Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Rigel Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Rigel Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.62 | 2.20 | 3.09 |
| Quick Ratio | 2.48 | 2.13 | 2.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $144.53 Million | $79.93 Million | $124.65 Million |
Rigel Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Rigel Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.21 |
| Latest Market Cap to Assets Ratio | 0.94 |
| Asset Growth Rate (YoY) | 213.2% |
| Total Assets | $513.59 Million |
| Market Capitalization | $481.79 Million USD |
Valuation Analysis
Near Book Valuation: The market values Rigel Pharmaceuticals Inc's assets close to their book value (0.94x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Rigel Pharmaceuticals Inc's assets grew by 213.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Rigel Pharmaceuticals Inc (1999–2025)
The table below shows the annual total assets of Rigel Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $513.59 Million | +213.21% |
| 2024-12-31 | $163.98 Million | +39.88% |
| 2023-12-31 | $117.22 Million | -12.70% |
| 2022-12-31 | $134.28 Million | -19.75% |
| 2021-12-31 | $167.33 Million | +51.60% |
| 2020-12-31 | $110.38 Million | -25.20% |
| 2019-12-31 | $147.57 Million | +6.08% |
| 2018-12-31 | $139.11 Million | +16.79% |
| 2017-12-31 | $119.11 Million | +52.44% |
| 2016-12-31 | $78.13 Million | -40.69% |
| 2015-12-31 | $131.75 Million | -14.52% |
| 2014-12-31 | $154.13 Million | -31.82% |
| 2013-12-31 | $226.06 Million | -27.09% |
| 2012-12-31 | $310.04 Million | +20.59% |
| 2011-12-31 | $257.11 Million | +37.71% |
| 2010-12-31 | $186.69 Million | +32.65% |
| 2009-12-31 | $140.74 Million | -2.16% |
| 2008-12-31 | $143.86 Million | +24.24% |
| 2007-12-31 | $115.79 Million | +2.25% |
| 2006-12-31 | $113.24 Million | -23.31% |
| 2005-12-31 | $147.67 Million | +87.34% |
| 2004-12-31 | $78.82 Million | +41.96% |
| 2003-12-31 | $55.52 Million | +25.22% |
| 2002-12-31 | $44.34 Million | -4.53% |
| 2001-12-31 | $46.45 Million | -27.72% |
| 2000-12-31 | $64.26 Million | +274.29% |
| 1999-12-31 | $17.17 Million | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more